GB2168055B - Method for promoting disuifide bond formation in recombinant proteins - Google Patents

Method for promoting disuifide bond formation in recombinant proteins

Info

Publication number
GB2168055B
GB2168055B GB08528017A GB8528017A GB2168055B GB 2168055 B GB2168055 B GB 2168055B GB 08528017 A GB08528017 A GB 08528017A GB 8528017 A GB8528017 A GB 8528017A GB 2168055 B GB2168055 B GB 2168055B
Authority
GB
United Kingdom
Prior art keywords
sup
recombinant proteins
promoting
bond formation
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08528017A
Other languages
English (en)
Other versions
GB2168055A (en
GB8528017D0 (en
Inventor
Kirston Edward Koths
Robert Forgan Halenbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725645&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2168055(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of GB8528017D0 publication Critical patent/GB8528017D0/en
Publication of GB2168055A publication Critical patent/GB2168055A/en
Application granted granted Critical
Publication of GB2168055B publication Critical patent/GB2168055B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
GB08528017A 1984-12-06 1985-11-13 Method for promoting disuifide bond formation in recombinant proteins Expired GB2168055B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/679,121 US4572798A (en) 1984-12-06 1984-12-06 Method for promoting disulfide bond formation in recombinant proteins

Publications (3)

Publication Number Publication Date
GB8528017D0 GB8528017D0 (en) 1985-12-18
GB2168055A GB2168055A (en) 1986-06-11
GB2168055B true GB2168055B (en) 1988-12-29

Family

ID=24725645

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08528017A Expired GB2168055B (en) 1984-12-06 1985-11-13 Method for promoting disuifide bond formation in recombinant proteins

Country Status (13)

Country Link
US (1) US4572798A (enExample)
EP (1) EP0185459B1 (enExample)
JP (1) JPH0696600B2 (enExample)
KR (1) KR940003475B1 (enExample)
AT (1) ATE84540T1 (enExample)
AU (1) AU594930B2 (enExample)
BR (1) BR8506101A (enExample)
CA (1) CA1248300A (enExample)
DE (1) DE3586987T2 (enExample)
ES (1) ES8700271A1 (enExample)
GB (1) GB2168055B (enExample)
IN (1) IN163025B (enExample)
ZA (1) ZA859001B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
CA1339757C (en) * 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
ATE156491T1 (de) * 1987-05-11 1997-08-15 Chiron Corp Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
US4801691A (en) * 1987-05-15 1989-01-31 International Minerals & Chemical Corp. Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
JP2669859B2 (ja) * 1987-08-04 1997-10-29 協和醗酵工業株式会社 タンパク質の再活性化法
US5759815A (en) * 1988-02-11 1998-06-02 Creative Biomolecules, Inc. Production of platelet derived growth factor (PDGF) an muteins thereof
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
JP2517100B2 (ja) * 1989-03-08 1996-07-24 協和醗酵工業株式会社 ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
US5204256A (en) * 1989-09-06 1993-04-20 Behringwerke Aktiengesellschaft Process for the purification of plasminogen activator inhibitor 2 (pai-2)
JPH05501500A (ja) * 1989-10-18 1993-03-25 クリエイティブ・バイオマリキュールズ・インコーポレーテッド ＴＧＦ―βの生合成構築物
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5252708A (en) * 1990-11-23 1993-10-12 Roussel Uclaf Preparation process for a protein containing at least one intramolecular disulphide bridge by oxidation, at a pH of less than 5.0 of corresponding reduced recombinant protein
IT1245063B (it) * 1991-04-12 1994-09-13 Ferruzzi Ricerca & Tec Procedimento per l'ossidazione di carboidrati
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
CN1113389A (zh) * 1993-08-04 1995-12-13 西巴-盖尔基股份公司 高分子量的脱硫水蛭素
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
AU735459B2 (en) 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
BR0213293A (pt) * 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
US20050008616A1 (en) 2003-07-11 2005-01-13 Schering Aktiengesellschaft Recombinant human interferon-beta-1b polypeptides
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
CA2759370C (en) 2009-04-30 2020-02-11 Peter Schotte Method for the production of domain antibodies
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
GB201101794D0 (en) * 2011-02-02 2011-03-16 Fermentas Uab Protein production
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183671A1 (en) * 2018-03-28 2019-10-03 Proteomics International Pty Ltd Methods for measuring relative oxidation levels of a protein
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
JPS5927858A (ja) * 1982-08-05 1984-02-14 Nippon Shinyaku Co Ltd ポリペプチドの製法
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
IE56372B1 (en) * 1982-12-22 1991-07-03 Genentech Inc Microbially produced rennet methods for its production and plasmids used for its production
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
AU5005285A (en) 1986-06-12
DE3586987D1 (de) 1993-02-25
EP0185459A2 (en) 1986-06-25
ZA859001B (en) 1986-08-27
BR8506101A (pt) 1986-08-19
ES549135A0 (es) 1986-09-01
GB2168055A (en) 1986-06-11
EP0185459B1 (en) 1993-01-13
AU594930B2 (en) 1990-03-22
JPS61140600A (ja) 1986-06-27
US4572798A (en) 1986-02-25
KR860005015A (ko) 1986-07-16
JPH0696600B2 (ja) 1994-11-30
CA1248300A (en) 1989-01-03
IN163025B (enExample) 1988-07-30
EP0185459A3 (en) 1989-02-08
KR940003475B1 (ko) 1994-04-22
ES8700271A1 (es) 1986-09-01
DE3586987T2 (de) 1993-05-13
ATE84540T1 (de) 1993-01-15
GB8528017D0 (en) 1985-12-18

Similar Documents

Publication Publication Date Title
ZA859001B (en) Method for promoting disulfide bond formation in recombinant proteins
US4530787B1 (enExample)
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
GR3021198T3 (en) Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
ES2020498T3 (es) Procedimiento para la activacion de proteinas eucarioticas heterologas, que tienen puentes de disulfuro, preparadas por tecnologia genetica, despues de su expresion en el seno de procariotas.
AU5609186A (en) Dietary products & uses comprising methylsulfonymethane
ZA951008B (en) N-terminally chemically modificed protein compositions and method
BR8700731A (pt) Composicao catalisadora
ATE44235T1 (de) Verwendung von kupfer und fettsaeulen.
AU577479B2 (en) Catalyst for reduction of nitrogen oxides
GB8326130D0 (en) Topical preparations containing tars and fatty acids
DE3665416D1 (en) Rhodium on carbon catalyst
AU2284188A (en) Improved process for recovering microbially produced interferon-beta
SE8800989D0 (sv) Dietary composition and process for preparing same
DE69120315D1 (de) Rekombinante DNA-Expressionsvektoren und DNA-Zusammensetzungen, die Isopenizillin N-Epimerase-Aktivität kodieren
SE8800988D0 (sv) Pharmaceutical compositons acting on the heart and cardiovascular system and process for preparing same
SE8800990D0 (sv) Skin-regenerating cosmetic compositon and process for preparing same
IE822714L (en) Preparation of 1-formyl congeners of indole-dihydroindole¹dimers
ATE291629T1 (de) Expressionssystem für die sekretion von bioaktivem, menschlichem granulozyt-makrophagem koloniestimulierungsfaktor (gm-csf) und anderen heterologen proteinen aus streptomyces
ATE15651T1 (de) Verwendung von aminosaeuren als pflanzenwachstums- promotoren und promotor-zusammensetzung.
BG60657B2 (bg) Човешки рекомбинантни интерлевкин-2 мутеини

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20051112